MD1003 (high doses of biotin) in progressive multiple sclerosis: subgroup analyses of the MS-SPI trial

Ayman Tourbah (1) , Christine Lebrun-Frenay , Gilles Edan (2, 3) , M. Clanet , C. Papex , S. Vukusic , J. de Sesze , Marc Debouverie , O. Gout , Pierre Clavelou , Gilles Defer , David A. Laplaud , Thibault Moreau , Pierre Labauge , Bruno Brochet , F. Sedel , J Pelletier

1 Hôpital Maison Blanche
2 Service de Neurologie [Rennes] = Neurology [Rennes]
3 CIC - Centre d'Investigation Clinique [Rennes]

no abstract

Domains: Life Sciences [q-bio]

Ayman Tourbah, Christine Lebrun-Frenay, Gilles Edan, M. Clanet, C. Papex, et al.. MD1003 (high doses of biotin) in progressive multiple sclerosis: subgroup analyses of the MS-SPI trial. Multiple Sclerosis Journal, 2015, 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, SPAIN, OCT 07-10, 2015, 21 (11), pp.785. ⟨hal-01259396⟩